Smith Asset Management Group Lp Lowers stake in Hologic (HOLX)

Hologic (HOLX) : Smith Asset Management Group Lp reduced its stake in Hologic by 0.96% during the most recent quarter end. The investment management company now holds a total of 1,552,243 shares of Hologic which is valued at $57,743,440 after selling 15,057 shares in Hologic , the firm said in a disclosure report filed with the SEC on Jul 26, 2016.Hologic makes up approximately 1.67% of Smith Asset Management Group Lp’s portfolio.

Other Hedge Funds, Including , Oakbrook Investments added HOLX to its portfolio by purchasing 26,200 company shares during the most recent quarter which is valued at $956,824. Hologic makes up approx 0.05% of Oakbrook Investments’s portfolio.Creative Planning boosted its stake in HOLX in the latest quarter, The investment management firm added 636 additional shares and now holds a total of 6,674 shares of Hologic which is valued at $238,929.

Hologic opened for trading at $38.28 and hit $38.605 on the upside on Friday, eventually ending the session at $38.49, with a gain of 0.57% or 0.22 points. The heightened volatility saw the trading volume jump to 25,53,587 shares. Company has a market cap of $10,678 M.

On the company’s financial health, Hologic reported $0.51 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Jul 27, 2016. Analyst had a consensus of $0.48. The company had revenue of $717.40 million for the quarter, compared to analysts expectations of $703.38 million. The company’s revenue was up 3.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.43 EPS.

Many Wall Street Analysts have commented on Hologic. Company shares were Reiterated by RBC Capital Mkts on Aug 1, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 39 from a previous price target of $37 .Hologic was Downgraded by Needham to ” Hold” on Apr 28, 2016.

Hologic Inc. is a developer manufacturer and supplier of diagnostics products medical imaging systems and surgical products. The Company’s business units are focused on diagnostics breast health GYN surgical and skeletal health. The Company’s diagnostics products include Aptima family of assays its ThinPrep system the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases chlamydia and gonorrhea certain high-risk strains of human papillomavirus (HPV) and Trichomonas vaginalis the parasite that causes trichomoniasis. The Company’s GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems an ultrasound-based osteoporosis assessment product and its Fluoroscan mini C-arm imaging products.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *